JP2023544142A5 - - Google Patents
Info
- Publication number
- JP2023544142A5 JP2023544142A5 JP2023519465A JP2023519465A JP2023544142A5 JP 2023544142 A5 JP2023544142 A5 JP 2023544142A5 JP 2023519465 A JP2023519465 A JP 2023519465A JP 2023519465 A JP2023519465 A JP 2023519465A JP 2023544142 A5 JP2023544142 A5 JP 2023544142A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- promoter
- mir
- sequence
- aimp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085922P | 2020-09-30 | 2020-09-30 | |
| US63/085,922 | 2020-09-30 | ||
| PCT/IB2021/059018 WO2022070142A1 (en) | 2020-09-30 | 2021-09-30 | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023544142A JP2023544142A (ja) | 2023-10-20 |
| JP2023544142A5 true JP2023544142A5 (https=) | 2025-03-06 |
Family
ID=80949802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519465A Pending JP2023544142A (ja) | 2020-09-30 | 2021-09-30 | ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240050527A1 (https=) |
| EP (1) | EP4221760A4 (https=) |
| JP (1) | JP2023544142A (https=) |
| KR (1) | KR20230110503A (https=) |
| CN (1) | CN116406304A (https=) |
| AU (1) | AU2021354969A1 (https=) |
| CA (1) | CA3192711A1 (https=) |
| WO (1) | WO2022070142A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10716866B2 (en) | 2018-03-29 | 2020-07-21 | Generoath Co., Ltd | Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof |
| KR102248420B1 (ko) * | 2019-03-15 | 2021-05-06 | 주식회사 제너로스 | miR-142-3p의 표적 서열을 포함하는 재조합 벡터 |
| CN119587566A (zh) * | 2022-07-22 | 2025-03-11 | 郑州大学 | 一种干预或治疗视网膜色素变性的生物制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060057992A (ko) * | 2004-11-24 | 2006-05-29 | 재단법인서울대학교산학협력재단 | ｐ38-ＤＸ2 및 이의 용도 |
| US7459529B2 (en) * | 2004-11-24 | 2008-12-02 | Seoul National University Industry Foundation | AIMP2-DX2 and its uses |
| CA2609142C (en) * | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| KR101749138B1 (ko) * | 2015-10-07 | 2017-06-20 | 원광대학교산학협력단 | 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도 |
| US10716866B2 (en) * | 2018-03-29 | 2020-07-21 | Generoath Co., Ltd | Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof |
| KR102248420B1 (ko) * | 2019-03-15 | 2021-05-06 | 주식회사 제너로스 | miR-142-3p의 표적 서열을 포함하는 재조합 벡터 |
-
2021
- 2021-09-30 CN CN202180066944.7A patent/CN116406304A/zh active Pending
- 2021-09-30 US US18/246,578 patent/US20240050527A1/en active Pending
- 2021-09-30 AU AU2021354969A patent/AU2021354969A1/en not_active Abandoned
- 2021-09-30 JP JP2023519465A patent/JP2023544142A/ja active Pending
- 2021-09-30 CA CA3192711A patent/CA3192711A1/en active Pending
- 2021-09-30 WO PCT/IB2021/059018 patent/WO2022070142A1/en not_active Ceased
- 2021-09-30 KR KR1020237014891A patent/KR20230110503A/ko active Pending
- 2021-09-30 EP EP21874708.7A patent/EP4221760A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544142A5 (https=) | ||
| JP2020203894A5 (https=) | ||
| ES2340499T3 (es) | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. | |
| JP2023113963A (ja) | 非組み込みウイルス送達システムおよびその使用の方法 | |
| EA007232B1 (ru) | Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью | |
| Deshane et al. | Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy | |
| JP2008106072A (ja) | 固型腫瘍、乳頭腫および疣贅の遺伝子治療 | |
| JPH09509060A (ja) | 遺伝子治療に使用できる宿主 − ベクタ系 | |
| JP2005530716A (ja) | ヒトにおける癌の治療方法 | |
| JP7291423B2 (ja) | ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用 | |
| JP2025120285A5 (https=) | ||
| JP2023536570A5 (https=) | ||
| JP2023544141A5 (https=) | ||
| US20060153805A1 (en) | Viral vectors and the use of the same for gene therapy | |
| CZ298710B6 (cs) | Kombinovaný lékový prípravek | |
| ES2198479T3 (es) | Vectores que llevan genes terapeuticos codificantes de peptidos antimicrobianos para terapia genica. | |
| HU226330B1 (en) | Anti-p53 single-chain antibody fragments and their uses to produce pharmaceutical compositions | |
| US6482803B1 (en) | Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A | |
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| JP2020516673A5 (https=) | ||
| JP2024540002A5 (https=) | ||
| US10130667B1 (en) | TAA/ecdCD40L oncolytic virus | |
| Vattemi et al. | Gene therapy for lung cancer: practice and promise. | |
| JP2020535203A5 (https=) | ||
| JP2022512667A5 (https=) |